TKPHF News Alert Takeda Pharmaceutica (TKPHF) 51.1000 02/15/2015
Post# of 64074
Posted On: 02/15/2015 4:55:43 PM
Takeda Pharmaceutica (TKPHF) 51.1000 $TKPHF
Interim results positive for Takeda blood cancer med
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 6:17AM CST
Canada accepts Sucampo's NDS for constipation med
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 6:38AM CST
SCMP: 15.32 (+0.04)
AMAG and Takeda part ways on ferumoxytol
Seeking Alpha - at Seeking Alpha - Mon Dec 29, 7:31AM CST
AMAG: 41.49 (+0.23)
Seattle Genetics down on ASH presentations
Seeking Alpha - at Seeking Alpha - Mon Dec 08, 11:37AM CST
SGEN: 31.57 (+0.36), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07), BMY: 60.04 (+0.56), CELG: 115.88 (+0.16), FPRX: 24.63 (+0.63)
Takeda's ixazomib a Breakthrough Therapy for amyloidosis
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 9:26AM CST
GE Healthcare and Takeda team up in liver disease R&D
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 10:22AM CST
Cell Source CEO, Itamar Shimrat on his firm's transition from preclinical to human clinical trials
ACCESSWIRE - Wed Nov 05, 8:02AM CST
LOS ANGELES, CA / ACCESSWIRE / November 5, 2014 / Overcoming graft rejection is the main obstacle when it comes to allogeneic stem cell regeneration and organ transplantation. Current treatment includes the use of systemic immunosuppression, which leaves the patient at risk for opportunistic infections. Recent breakthroughs from Cell Source (OTC: CLCS) in Veto Cell technology, which selectively tunes immune response, may change how immunologists treat blood cancers and bone marrow transplants, as well as the process of how organs are repaired and new ones are regenerated.
MRK: 58.81 (-0.07), SHPG: 239.82 (+6.11)
Takeda's (TKPHF) CEO Yasuchika Hasegawa on Q2 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Oct 31, 10:58PM CDT
Actos punitive damage award slashed
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 7:26AM CDT
LLY: 70.56 (+0.03)
EC approves ulcerative colitis med
Seeking Alpha - at Seeking Alpha - Wed Oct 22, 10:31AM CDT
SGYP: 2.98 (unch), JNJ: 99.62 (+1.18), ABT: 46.09 (+0.87), CNDO: 2.28 (+0.03), PFE: 34.64 (-0.23), SHPG: 239.82 (+6.11), VBLX: 11.15 (+0.15), SLXP: 152.35 (+3.17), RCPT: 115.83 (-0.66), ABBV: 58.05 (+1.00), ATHX: 2.12 (unch)
Orexigen earns $70M milestone
Seeking Alpha - at Seeking Alpha - Wed Oct 15, 9:33AM CDT
OREX: 5.55 (+0.10)
Interim results positive for Takeda blood cancer med
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 6:17AM CST
Canada accepts Sucampo's NDS for constipation med
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 6:38AM CST
SCMP: 15.32 (+0.04)
AMAG and Takeda part ways on ferumoxytol
Seeking Alpha - at Seeking Alpha - Mon Dec 29, 7:31AM CST
AMAG: 41.49 (+0.23)
Seattle Genetics down on ASH presentations
Seeking Alpha - at Seeking Alpha - Mon Dec 08, 11:37AM CST
SGEN: 31.57 (+0.36), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07), BMY: 60.04 (+0.56), CELG: 115.88 (+0.16), FPRX: 24.63 (+0.63)
Takeda's ixazomib a Breakthrough Therapy for amyloidosis
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 9:26AM CST
GE Healthcare and Takeda team up in liver disease R&D
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 10:22AM CST
Cell Source CEO, Itamar Shimrat on his firm's transition from preclinical to human clinical trials
ACCESSWIRE - Wed Nov 05, 8:02AM CST
LOS ANGELES, CA / ACCESSWIRE / November 5, 2014 / Overcoming graft rejection is the main obstacle when it comes to allogeneic stem cell regeneration and organ transplantation. Current treatment includes the use of systemic immunosuppression, which leaves the patient at risk for opportunistic infections. Recent breakthroughs from Cell Source (OTC: CLCS) in Veto Cell technology, which selectively tunes immune response, may change how immunologists treat blood cancers and bone marrow transplants, as well as the process of how organs are repaired and new ones are regenerated.
MRK: 58.81 (-0.07), SHPG: 239.82 (+6.11)
Takeda's (TKPHF) CEO Yasuchika Hasegawa on Q2 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Oct 31, 10:58PM CDT
Actos punitive damage award slashed
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 7:26AM CDT
LLY: 70.56 (+0.03)
EC approves ulcerative colitis med
Seeking Alpha - at Seeking Alpha - Wed Oct 22, 10:31AM CDT
SGYP: 2.98 (unch), JNJ: 99.62 (+1.18), ABT: 46.09 (+0.87), CNDO: 2.28 (+0.03), PFE: 34.64 (-0.23), SHPG: 239.82 (+6.11), VBLX: 11.15 (+0.15), SLXP: 152.35 (+3.17), RCPT: 115.83 (-0.66), ABBV: 58.05 (+1.00), ATHX: 2.12 (unch)
Orexigen earns $70M milestone
Seeking Alpha - at Seeking Alpha - Wed Oct 15, 9:33AM CDT
OREX: 5.55 (+0.10)
(0)
(0)Scroll down for more posts ▼